Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Sanofi | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Sanofi

Pharmaceuticals sales up 3% in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sanofi
3Q Revenues: €9.1 billion (flat)
3Q Earnings: €2.9 billion (-1%)
YTD Revenues: €26.4 billion (+6%)
YTD Earnings: €7.7 billion (+7%)
Comments: Pharmaceuticals sales were up 3% to €7.1 billion in the quarter. Sanofi Genzyme sales were up 14% at CER to €1.4 billion due to the strong U.S. launch of Dupixent and growth in Multiple Sclerosis. Lantus sales were €867 million, down 25%. Toujeo sales were up 9% to €179 million. Cerezyme sales were down 6% to €119 million. Myozyme sales were €166 million, up 4%. Fabrazyme sales were up 4% to €158 million. Diabetes and Cardiovascular sales declined 15% to €1.3 billion. Plavix sales were down 11% to €358 million. Lovenox sales were down 8% to €370 million. Renagel sales were down 38%. Sanofi Pasteur grew 11% to €1.9 billion at CER driven by pediatric combinations and booster vaccines. Polio/Pertussis/Hib sales were up 34% to €433 million. Influenza vaccine sales were €951 million down 4%. Meningitis/Pneumonia sales were €252 million, down 1%. Adult booster sales were up 38% to €143 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters